JPRN-UMIN000001919
Completed
Phase 2
Randomized phase II study comparing chemotherapy led by using the classification of primary tumor origin with empirical chemotherapy for patients with unknown primary cancer . - Randomized phase II study for patients with unknown primary cancer.
Ministry of Health, Labour and Welfare scientific research Nakagawa squad0 sites120 target enrollmentApril 30, 2009
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ministry of Health, Labour and Welfare scientific research Nakagawa squad
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)cases with the adaptation of radical operation and the radical irradiation (2\)Patient subgroups known to have favorable features are excluded. These subgroups include as follows: (a)women with adenocarcinoma involving only axillary lymph nodes (b)women with adenocarcinoma involving the peritoneal cavity (c)patients with squamous cell carcinoma involving only cervical lymph nodes (d)patients with squamous cell carcinoma involving only inguinal lymph nodes (e)patients with poorly differentiated carcinoma consistent with a germ cell tumor or neuroendcrine carcinomas (f)men with osteosclerosis\-related bone metastases and elevated PSA in their plasma or tumor (3\)active infection or other severe complications (such as gastrointestinal bleeding, heart disease) (4\)symptomatic brain tumor (5\)interstitial pneumonitis or pulmonary fibrosis (6\)patients who underwent bone marrow transplantation (7\)patients who underwent peripheral blood stem cell transplantation (8\)severe drug allergy (9\)alcohol intolerance (10\) HBsAg(\+) (11\)pregnant or lactating women (12\)men with the pregnant intention (13\)uncontrollable diabetis mellitus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients - NDWomen with histologic or cytologic diagnosis of advanced breast cancer, who have received one prior chemotherapy containing anthracyclines as neo adjuvant or palliative 1st-line treatment and one prior chemotherapy containing taxanes as neo adjuvant or palliative 1st-line treatment.MedDRA version: 8.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2006-000441-19-ITELI LILLY160
Active, not recruiting
Not Applicable
A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.advanced breast cancerMedDRA version: 8.0Level: LLTClassification code 10006285EUCTR2006-000441-19-DEEli lilly and Company Limited144
Active, not recruiting
Not Applicable
Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer. - NDpancreas metastatic tumorMedDRA version: 9.1Level: HLTClassification code 10033632EUCTR2010-020979-23-ITFONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
Active, not recruiting
Not Applicable
Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma. - IELSG 32EUCTR2009-012432-32-GBniversity Hospital Southampton NHS Foundation Trust126
Completed
Phase 2
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS LymphomaCentral Nervous System LymphomaDRKS00003763niversitätsklinikum Freiburg, Abt. Med 1, Hämatologie/ Onkologie227